- Home
- Companies
- MedChemExpress LLC (MCE)
- Products
- MedChemExpress - Model Empasiprubart - ...
MedChemExpress - Model Empasiprubart -2579031-19-7
MCE products for research use only. We do not sell to patients.
Empasiprubart
MCE China:Empasiprubart
Brand:MedChemExpress (MCE)
Cat. No.HY-P990025
CAS:2579031-19-7
Synonyms:ARGX-117
Purity:97.93%
Storage:Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping:Shipping with dry ice.
Description:Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models.
In Vitro:Empasiprubar prevents complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection in an in vitro model[1]. Empasiprubar can inhibit C4 downstream complement activation induced by anti-GM1 antibody binding to motor neurons (MN) derived from induced pluripotent stem cells (iPSC) model[3].
In Vivo:Empasiprubart (0.5-30 mg/kg; once daily; 60 days; i.v.) targets the classical pathway (CP) and lectin pathway (LP) inhibition in crab eating macaques, without affecting the alternative pathway (AP)[1]. Empasiprubart (200 mg/kg; once; i.v.) can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models[2].
Species:Humanized
Isotype:Human IgG1 kappa
Recommend Isotype Controls:Human IgG1 kappa, Isotype Control
Hot selling product:Clarithromycin | PAR-4 Agonist Peptide, amide (TFA) | 2OH-BNPP1 | Pimozide | Sintilimab | ATP-polyamine-biotin | TAPI-2 | Fmoc-Gly-Gly-Phe-OH | Prim-O-glucosylcimifugin | Glycine
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
References:
[1]. Van de Walle I, et al. ARGX-117, a therapeutic complement inhibiting antibody targeting C2. J Allergy Clin Immunol. 2021 Apr;147(4):1420-1429.e7. [Content Brief]
[2]. Campbell CI, et al. Complement inhibition prevents glial nodal membrane injury in a GM1 antibody-mediated mouse model. Brain Commun. 2022 Nov 23;4(6):fcac306. [Content Brief]
[3]. Budding K, et al. Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy. Neurol Neuroimmunol Neuroinflamm. 2021 Nov 10;9(1):e1107. [Content Brief]
Brand introduction:
• MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world;
• More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas;
• The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects;
• Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services;
• It has a professional experimental center and strict quality control and verification system;
• Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products;
• The biological activity of the products has been verified by the experiments of customers in various countries;
• A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers;
• Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world;
• It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。
